R-2487

The global rheumatoid arthritis market is projected to grow from $28 billion in 2024 to $34.7 billion by 2035, with a CAGR of 1.97%, fueled by advancements in biologics and targeted therapies.

Rise Therapeutics has completed the dose escalation stages for R-2487 and R-3750 clinical trials, advancing both oral immunotherapies to dose expansion.

Rise Therapeutics has dosed the first patient in its Phase 1 clinical trial evaluating R-2487 for rheumatoid arthritis, marking a key milestone for the company.

Rise Therapeutics received FDA clearance for its IND application to begin a Phase 1 clinical trial of R-2487, an oral immunotherapy for rheumatoid arthritis.

Rise Therapeutics is currently conducting a Phase 1 clinical trial for R-3750, an oral immune therapy, in patients with mild to moderate ulcerative colitis.